NO953621L - Nye benzopyranderivater, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem - Google Patents

Nye benzopyranderivater, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem

Info

Publication number
NO953621L
NO953621L NO953621A NO953621A NO953621L NO 953621 L NO953621 L NO 953621L NO 953621 A NO953621 A NO 953621A NO 953621 A NO953621 A NO 953621A NO 953621 L NO953621 L NO 953621L
Authority
NO
Norway
Prior art keywords
group
case
hydrogen
bond
hydrogen atom
Prior art date
Application number
NO953621A
Other languages
English (en)
Other versions
NO953621D0 (no
Inventor
Genevieve Baziard-Mouysset
Sallouma Younes
Youssef Labssita
Marc Payard
Daniel-Henri Caignard
Pierre Renard
Marie-Claire Rettori
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of NO953621D0 publication Critical patent/NO953621D0/no
Publication of NO953621L publication Critical patent/NO953621L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Derivater med den generelle formel (I):. jhvorAr betyr en fenyl-, naftyl-, substituert fenyl- eller substituert naftylgruppe,n representerer et helt tall mellom 1 og 4, RB representerer en alkylgruppe, og i dette tilfelle representerer A en enkelt binding og RA og RC, som er identiske eller forsjellige, representerer uavhengig av hverandre, et hydrogenatom eller en gruppe valgt fra halogen, alkyl, alkyl substituert med ett eller flere antall halogenatomer, og alkoksy,eller RB og RC sammen danner en -(CH,)q- bro, hvor q har verdien 0, 1 eller 2, og i dette tilfellet representerer A en -(CH)p-bro, hvor p representerer 0, 1 eller 2 og således at p < q = 1 eller 2, og i dette tilfellet representerer RA en hydroksyl- eller alkoksygruppe, bundet i 5-stillingen av den aromatiske ring som bærer den, eller RA representerer et hy-drogen- eller halogenatom, i enhver stilling på den aromatiske ring,eller RB og RC sammen danner en -CH= bro, og bindingen som binder den til den aromatiskering er en enkelt binding, og i dette tilfellet representerer A en CH-gruppe og RA representerer et hydrogenatom eller en hydroksyl-eller alkoksygruppe bundet i 5-atillingen av den aromatiske ring som bærer den,eller RB og RC danner sammen en enkeltbinding og da representerer A en gruppe. idet karbonylgruppen er bundet til oksygenet og bindingen som forbinder A til karbonatomet. som bærer sidekjeden er en dobbeltbinding, og i dette tilfellet representerer RA et hydrogenatom eller en hydroksy- eller alkoksygruppe,. når RB representerer en alkylgruppe, X og Y. hver representerer to hydrogenatomer eller. danner, sammen med karbonatomet som bærer dem, en C«=0-gruppe, og RD representerer et hydrogenatom eller en alkylgruppe,. når RB og RC danner en bro, representerer X og Y hver to hydrogenatomer og RD, som bare ek-sisterer når alle bindingene for karbonatomene som bærer dem er enkeltbindinger, representerer et hydrogenatom.
NO953621A 1994-09-15 1995-09-14 Nye benzopyranderivater, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem NO953621L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9410987A FR2724656B1 (fr) 1994-09-15 1994-09-15 Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
NO953621D0 NO953621D0 (no) 1995-09-14
NO953621L true NO953621L (no) 1996-03-18

Family

ID=9466947

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953621A NO953621L (no) 1994-09-15 1995-09-14 Nye benzopyranderivater, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem

Country Status (16)

Country Link
US (2) US5691340A (no)
EP (1) EP0702010B1 (no)
JP (1) JP3061747B2 (no)
CN (1) CN1054848C (no)
AT (1) ATE190612T1 (no)
CA (1) CA2158484C (no)
DE (1) DE69515580T2 (no)
DK (1) DK0702010T3 (no)
ES (1) ES2146297T3 (no)
FI (1) FI954304L (no)
FR (1) FR2724656B1 (no)
GR (1) GR3033508T3 (no)
NO (1) NO953621L (no)
NZ (1) NZ280019A (no)
PT (1) PT702010E (no)
ZA (1) ZA957793B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751645B1 (fr) * 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
SK13652002A3 (sk) * 2000-03-31 2004-01-08 Pfizer Products Inc. Deriváty piperazínu
JPWO2003040382A1 (ja) * 2001-11-09 2005-03-03 株式会社カネカ 光学活性クロマン誘導体の製造法および中間体
CN1938029A (zh) * 2004-02-06 2007-03-28 舍林股份公司 具有趋化因子抑制作用的哌嗪衍生物及其在治疗多发性骨髓瘤中的应用
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
SG163518A1 (en) * 2004-06-24 2010-08-30 Incyte Corp Amido compounds and their use as pharmaceuticals
US20060009491A1 (en) * 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
US7687665B2 (en) 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
MXPA06014573A (es) * 2004-06-24 2007-03-12 Incyte Corp Compuestos amido y su uso como farmaceuticos.
US20060122197A1 (en) * 2004-08-10 2006-06-08 Wenqing Yao Amido compounds and their use as pharmaceuticals
CA2585797C (en) * 2004-11-10 2015-01-06 Incyte Corporation Lactam compounds and their use as pharmaceuticals
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
JP2008520700A (ja) * 2004-11-18 2008-06-19 インサイト・コーポレイション １１−βヒドロキシルステロイドデヒドロゲナーゼタイプＩの阻害剤およびその使用方法
WO2007038138A2 (en) * 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
EP1957494A2 (en) * 2005-12-05 2008-08-20 Incyte Corporation Lactam compounds and methods of using the same
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
BRPI0707408A2 (pt) * 2006-01-31 2011-05-03 Incyte Corp compostos de amido e seu uso como produtos farmacêuticos
WO2007101270A1 (en) * 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007103719A2 (en) * 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007130898A1 (en) * 2006-05-01 2007-11-15 Incyte Corporation TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1
JP2009537564A (ja) * 2006-05-17 2009-10-29 インサイト・コーポレイション １１−βヒドロキシルステロイドデヒドロゲナーゼタイプＩの複素環阻害剤およびそれを用いる方法
CL2008001839A1 (es) * 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
CN103724296B (zh) * 2013-12-12 2015-09-02 南京医科大学 芳基取代的哌嗪羰基衍生物及其制备方法和应用
CN105609315B (zh) * 2015-12-23 2018-02-02 丰宾电子（深圳）有限公司 一种抗震型牛角铝电解电容器
CN110372638B (zh) * 2018-04-13 2023-09-22 中国药科大学 哌嗪类ampk激动剂及其医药用途
JP2023541960A (ja) 2020-09-17 2023-10-04 メレティオス セラピューティクス ウイルス感染を治療するための化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459860A (en) * 1967-06-09 1969-08-05 Ciba Geigy Corp 2-aminomethyl-2,3-dihydrobenzofurans as antihypertensive agents
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
DE3139970A1 (de) * 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
EP0202580B1 (en) * 1985-05-13 1990-03-28 Kuraray Co., Ltd. 3,4-dihydrobenzopyran derivatives
JPS6219577A (ja) * 1985-07-16 1987-01-28 Kanebo Ltd 新規なベンジルピペラジン誘導体および該化合物を有効成分とする医薬組成物
FR2618437B1 (fr) * 1987-07-23 1989-11-17 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les medicaments qui les contiennent
EP0551617A3 (en) * 1991-12-13 1993-11-03 Ube Industries Cinnamyl piperazine derivatives method of manufacturing the same and agricultural/horticultural fungicides containing cinnamyl piperazine derivatives
EP0566189A1 (en) * 1992-04-13 1993-10-20 Akzo N.V. Psychotropic piperazine derivative
FR2694005B1 (fr) * 1992-07-21 1994-08-26 Adir Nouvelles aminoalkylchromones, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
DE4233963A1 (de) * 1992-10-08 1994-04-14 Schwabe Willmar Gmbh & Co Neue Benzopyranone, Verfahren zu ihrer Herstellung und Verwendung
US5364867A (en) * 1992-11-30 1994-11-15 Sterling Winthrop Inc. 4-phenylpiperdine agents for treating cns disorders

Also Published As

Publication number Publication date
ATE190612T1 (de) 2000-04-15
FI954304A7 (fi) 1996-03-16
JP3061747B2 (ja) 2000-07-10
NZ280019A (en) 1996-03-26
PT702010E (pt) 2000-06-30
FI954304L (fi) 1996-03-16
AU3059995A (en) 1996-03-28
EP0702010B1 (fr) 2000-03-15
FR2724656B1 (fr) 1996-12-13
FR2724656A1 (fr) 1996-03-22
DK0702010T3 (da) 2000-08-14
CA2158484A1 (fr) 1996-03-16
US5691340A (en) 1997-11-25
ES2146297T3 (es) 2000-08-01
DE69515580D1 (de) 2000-04-20
JPH0881451A (ja) 1996-03-26
US5668138A (en) 1997-09-16
AU684660B2 (en) 1997-12-18
ZA957793B (en) 1996-05-07
CA2158484C (fr) 2001-08-14
DE69515580T2 (de) 2001-06-13
CN1132202A (zh) 1996-10-02
GR3033508T3 (en) 2000-09-29
FI954304A0 (fi) 1995-09-13
CN1054848C (zh) 2000-07-26
NO953621D0 (no) 1995-09-14
EP0702010A1 (fr) 1996-03-20

Similar Documents

Publication Publication Date Title
NO953621L (no) Nye benzopyranderivater, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20083446L (no) Fenyl-piperazinderivater som serotonin-reopptaksinhibitorer
NO20080460L (no) Nytt pyridinderivat og pyrimidinderivat (3)
NO20074718L (no) BCRP/ABCG2 inhibitor
WO2009069523A1 (ja) アミン系高分子化合物及びそれを用いた発光素子
WO2009066641A1 (ja) 縮合芳香族誘導体及びそれを用いた有機エレクトロルミネッセンス素子
DE602007010194D1 (de) Neue Sulfoniumverbindung, diese enthaltende lichtempfindliche Zusammensetzung und Strukturbildungsverfahren unter Verwendung der lichtempfindlichen Zusammensetzung
JP2006096962A5 (no)
ATE331304T1 (de) Halbleiter auf basis von substituiertem pentacen
TW200510377A (en) Novel compound having 4-pyridylalkylthio group as substituent
IS7118A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfnæmissjúkdómum
DK167085D0 (da) Fremgangsmaade til modificering af smag
TW200503686A (en) Cannabinoid receptor modulator
DE69918465D1 (de) Sulfonamidhydroxamate
NO20004144L (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykininreseptorantagonister
BR0109176A (pt) Método para preparação de citalopram e composto da fórmula
HRP20080262T3 (hr) Derivati 4-(2-feniloksifenil)-piperidin ili -1,2,3,6 tetrahidropiridin kao inhibitori ponovne apsorpcije serotonina
ES471503A1 (es) Procedimiento para la obtencion de amino-dihidropiridinas
AU2251801A (en) Piperidine derivatives and their use as serotonin receptor antagonists
UA90856C2 (ru) Бензопирановое соединение
CA2425368A1 (en) New sulphoxybenzamides
DE69709357D1 (de) Campothecinderivate, isoliert aus mappia foetida, und ihre verwendung als arzneimittel
CO4750812A1 (es) Nuevos taxoides, su preparacion y las composiciones farma- ceuticas que los contienen
DK1250335T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner
Thomas Terpenoids Derived from Linalyl Oxide. Part 5. 2‐(2‐Methyl‐2‐vinyltetrahydrofur‐5‐yl)‐2, 6, 6‐trimethyl‐2, 6‐dihydropyr‐3‐one, a new sesquiterpenoid isolated from Artemisia Pallens

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application